Review of Combination of Peritoneal Dialysis and Hemodialysis as a Modality of Treatment for End‐stage Renal Disease
Review of Combination of Peritoneal Dialysis and Hemodialysis as a Modality of Treatment for End‐stage Renal Disease
复制标题
腹膜透析和血液透析联合治疗终末期肾病的回顾
DOI：
10.1111/j.1526-0968.2004.00107.x
复制
发表时间：
2004
影响因子：
1.9
通讯作者：
S. Watanabe
中科院分区：
文献类型：
--
作者：
H. Fukui;S. Hara;Y. Hashimoto;T. Horiuchi;M. Ikezoe;N. Itami;M. Kawabe;H. Kawanishi;H. Kimura;Y. Nakamoto;M. Nakayama;M. Ono;K. Ota;T. Shinoda;T. Suga;T. Ueda;M. Fujishima;T. Maeba;A. Yamashita;Y. Yoshino;S. Watanabe
摘要：由于在持续性非卧床腹膜透析（CAPD）中，残余肾功能（RRF）对总溶质清除率的贡献通常很大，如果不采取适当的处方管理策略，RRF随时间的丧失可能导致透析不充分。此外，腹膜渗透性增加引起的超滤下降可能会限制CAPD治疗的继续。腹膜透析和血液透析（PD + HD）联合治疗（补充透析治疗）是一种替代方法。 这种疗法允许患者维持日常活动，与CAPD一样，同时接受每周一次的HD补充剂，以消除溶质和水分的不足。这种治疗允许PD患者继续PD，而不会转为全HD，即使在PD处方个性化后仍有尿毒症症状。这种治疗方案在心理上更容易为患者所接受，并有望提供腹膜休息、改善生活质量和降低医疗费用等伴随的有益效果。
Abstract: Because the contribution of residual renal function (RRF) to total solute clearance is often significant in continuous ambulatory peritoneal dialysis (CAPD), loss of RRF over time can lead to inadequate dialysis if appropriate prescription management strategies are not pursued. Additionally, declines in ultrafiltration caused by increases in peritoneal permeability may limit continuation of CAPD therapy. Peritoneal dialysis and hemodialysis (PD + HD) combination therapy (complementary dialysis therapy) is an alternative method. This therapy allows the patient to maintain daily activities, as with CAPD, while undergoing once‐a‐week HD supplements for the insufficient removal of solutes and water. This therapy allows for the continuation of PD without shifting to total HD in PD patients who continue to have uremic symptoms even after individualization of the PD prescription. This treatment option is psychologically more acceptable to patients and may be expected to provide such accompanying beneficial effects as peritoneal resting, improvement of QOL and reduction in medical cost.